May 3, 2024 10:31 AM EDT
News Briefing

Roy­al­ty Phar­ma's mile­stone pay­ment to Ar­row­head; Abeon­a's $75M of­fer­ing

ENDPOINTS

Plus, news about Soleno, No­vo Nordisk and Car­dior Phar­ma­ceu­ti­cals:

Roy­al­ty Phar­ma pays Ar­row­head Phar­ma­ceu­ti­cals: The $50 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times